NOTCH3 and breast cancer: In a phase I trial (NCT02129205), 40 patients with advanced breast cancer (BC) and other solid tumors unselected for Notch3 expression were studied for safety, pharmacokinetics, immunogenicity, and early anticancer efficacy of single-agent PF-06650808.